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Objectives
Infection with hepatitis C virus (HCV) is a major cause of chronic liver disease. High HCV RNA
levels have been associated with poor treatment response. This study aimed to examine the
natural history of HCV RNA in chronically HCV/HIV-coinfected individuals.
Methods
Mixed models were used to analyse the natural history of HCV RNA changes over time in
HIV-positive patients with chronic HCV infection.
Results
A total of 1541 individuals, predominantly White (91%), male (73%), from southern (35%) and
western central Europe (23%) and with HCV genotype 1 (58%), were included in the analysis.
The median follow-up time was 5.0 years [interquartile range (IQR) 2.8 to 8.3 years]. Among
patients not on combination antiretroviral therapy (cART), HCV RNA levels increased by a mean
27.6% per year [95% confidence interval (CI) 6.1-53.5%; P = 0.0098]. Among patients receiving
cART, HCV RNA levels were stable, increasing by a mean 2.6% per year (95% CI -1.1 to 6.5%;
P = 0.17). Baseline HCV RNA levels were 25.5% higher (95% CI 8.8 to 39.1%; P = 0.0044) in
individuals with HCV genotype 1 compared with HCV genotypes 2, 3 and 4. A 1 log HIV-1 RNA
copies/mL increase in HIV RNA was associated with a 10.9% increase (95% CI 2.3 to 20.2%;
P = 0.012) in HCV RNA.
Conclusions
While HCV RNA levels increased significantly in patients prior to receiving cART, among those
treated with cART HCV RNA levels remained stable over time.
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Introduction
Of the 35 million people currently living with HIV world-
wide, approximately 20% have chronic hepatitis C virus
(HCV) infection [1–3]. Coinfection with HCV is one of
the most clinically important comorbidities in the HIV-
infected population [1–3]. In recent years, mortality rates
attributable to HIV infection have decreased as a result of
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antiretroviral therapy [4–6]. As a result, end-stage liver
disease has assumed increasing importance as a cause of
death among the coinfected population [4–6]. This is espe-
cially true for injecting drug users (IDUs), in whom HCV
coinfection is common as a result of shared transmission
routes [2,4].
Anti-HCV antibody (HCVAb) positivity has been associ-
ated with a higher rate of any-cause death and liver-related
death [6–10], while plasma HCV RNA, along with HCV
genotype and the interleukin (IL)-28B gene variant, has
been shown to be one of the most important predictors of
sustained virological response (SVR) to pegylated Inter-
feron (peg-IFN) and ribavirin (RBV) in coinfected individu-
als [1,4,11–13]. Furthermore, it has been reported that an
HCV RNA measurement taken early after HIV seroconver-
sion can predict progression to AIDS and death in indi-
viduals with high HCV viral loads [14]. Although HCV RNA
has been reported to stay relatively stable over time in
monoinfected individuals [4,15,16], the course of HCV RNA
in coinfected individuals is less well characterized [4,17].
The aim of this study was to examine the change over
time in HCV RNA levels in HIV/HCV-coinfected individuals
to investigate which factors affect baseline levels and the
rate of change over time in HCV RNA.
Methods
Study participants
The EuroSIDA study is a prospective, observational cohort
study of 16594 HIV-positive individuals in 105 centres
across Europe, Israel and Argentina. The study has been
described in detail previously [18]. In brief, HIV-positive
individuals were enrolled into eight cohorts from May 1994
onwards and the median follow-up period of individuals in
the cohort is currently to April 2011. Information is col-
lected on a standardized data collection form (available at
www.cphiv.dk) every 6 months, including all CD4 T-cell
counts and viral loads measured since the last follow-up
visit and starting and stopping dates of all antiretroviral
(ARV) drugs. The dates of diagnosis of all AIDS-defining
illnesses, non-AIDS-defining malignancies and other
serious infections are also recorded.
Information on HCVAb status has been collected since
1997; persons who died or were lost to follow-up before
this date did not routinely have information on HCVAb
status collected. Centres that have determined HCV geno-
type or measured HCV RNA are requested to provide
that information to the coordinating centre. The EuroSIDA
plasma repository was set up in 1997 and aims to collect
plasma samples from individuals at 6-monthly intervals.
Individuals with unknown HCVAb status and a stored
plasma sample were identified in 2006 and HCVAb status
was determined. Individuals who tested positive for HCVAb
were then tested for plasma HCV RNA and genotype in a
reference laboratory. In addition, individuals with known
HCVAb status but unknown HCV genotype were identified
and those with stored samples were also tested for plasma
HCV RNA and genotype.
Plasma HCV RNA was investigated and quantified in
HCVAb-positive samples by means of the Versant HCV-RNA
assay (version 3.0; Bayer Diagnostics, Levekusen, Germany),
which uses a signal amplification procedure with a linear
dynamic range of 615 to 1 ¥ 107 IU/ml. Coordinating centres
that provide plasma HCV RNA have not previously been
required to stipulate which assay was used in determining
the HCV RNA level, only to provide the units that it is
measured in. Coordinating centres submit HCV RNA data in
both copies/ml and IU/ml, but for the purposes of this study
we include only data recorded in IU/ml.
HCV genotyping was performed using the LiPA HCV
genotype assay (version 2.0; Innogenetics, Gent, Belguim).
Information on the assays used to determine plasma HCV
RNA and genotype has been previously provided [19].
Statistical analysis
All HCVAb-positive individuals with positive quantitative
HCV RNA measurements, considered chronically infected
with HCV, were included in these analyses. HCV RNA
measurements taken after individuals had started HCV
treatment and those at the upper limit of detection in
earlier assays with narrower detection ranges (41 measure-
ments in 39 people) were not included. Baseline in the
analysis was defined as the date of the first HCV RNA
measurement for each individual. Individuals were fol-
lowed until their last HCV RNA measurement while HCV
treatment naïve. Follow-up was from May 1994 to April
2011; the median date of last HCV RNA measurement prior
to treatment for HCV infection was May 2003.
Linear mixed models were used to assess which factors
were associated with HCV RNA levels (in log10 IU/ml). Such
models allow investigation of whether HCV RNA levels
vary at baseline and whether the rate of change over time
varies for different factors. Factors considered were: time
(from first measurement), age, sex, race, region of Europe,
HIV risk/exposure group, HCV genotype, time since first
HIVAb positive and the calendar year of the baseline
HCV RNA measurement. Hepatitis B virus surface antigen
(HBsAg) status, HIV viral load, CD4 cell count and cART
status [a protease inhibitor (PI) regimen was defined as
containing a PI and at least two other ARVs not including
a nonnucleoside reverse transcriptase inhibitor (NNRTI), an
NNRTI regimen was defined as containing an NNRTI and at
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least two other ARVs not including a PI, and a more
inclusive definition of any cART was at least three ARVs
from any class] were included as time updating variables.
Time from baseline HCV RNA measurement and the inter-
cept were modelled as random effects. An unstructured
covariance structure was used throughout.
Multivariable logistic regression models were used to
assess which factors were associated with increases and
decreases in HCV RNA levels and which factors were asso-
ciated with reaching a threshold of 800 000 IU/ml, which
has been shown to be associated with a poor response to
treatment for HCV infection [12].
All analyses were performed using SAS version 9.2 (SAS
Institute, Cary, NC).
Results
There were 14324 patients in EuroSIDA with HCVAb status
reported, of whom 4664 were HCVAb positive. Of these,
2670 had HCV RNA data available and 2115 (79.2%) were
chronically infected (HCV RNA positive); 1541 had their
HCV RNA data recorded in IU/ml with data available
on covariates of interest and were eligible for inclusion
in this analysis. HCVAb-positive patients without HCV
RNA data, who were excluded from this study, were older
at the time of their HCVAb-positive test result [odds ratio
(OR) 1.37 per 10 years; 95% confidence interval (CI) 1.20–
1.56; P < 0.0001] and were more likely to reside in eastern
central or eastern Europe [OR 3.31 (95% CI 2.29–4.79;
P < 0.0001) and OR 8.05 (95% CI 5.45–11.88; P < 0.0001)
compared with western Europe, respectively] than those
with HCV RNA data, who were included in the study.
Baseline characteristics of the 1541 individuals included
in the analysis are shown in Table 1. They were predomi-
nantly White (91%), IDUs (73%), male (69%), and from
southern (35%) and western central Europe (23%); 58% had
HCV genotype 1 while 3, 26 and 14% had HCV genotypes
2, 3 and 4, respectively. Eighty one per cent were HBsAg
Table 1 Baseline characteristics of 1541 included individuals by combination antiretroviral therapy (cART) status at baseline
Total (n = 1541) Off cART (n = 393) On cART (n = 1148) P-value*
Gender [n (%)]
Male 1070 (69.4) 263 (66.9) 807 (70.3) 0.21
Female 471 (30.6) 130 (33.1) 341 (29.7)
Race [n (%)]
White 1405 (91.2) 365 (92.9) 1040 (90.6) 0.17
Nonwhite 136 (8.8) 28 (7.1) 108 (9.4)
Age (years) [median (IQR)] 37.5 (32.1–42.1) 33.9 (27.6–39.0) 38.4 (33.6–43.0) < 0.0001
Region of Europe/country [n (%)]
Southern 540 (35.0) 111 (28.2) 429 (37.4) < 0.0001
Western central 348 (22.6) 78 (19.9) 270 (23.5)
Northern 229 (14.9) 69 (17.6) 160 (13.9)
Eastern central 246 (16.0) 42 (10.7) 204 (17.8)
Eastern 145 (9.4) 89 (22.7) 56 (4.9)
Argentina 33 (2.1) 4 (1.0) 29 (2.5)
HIV exposure group [n (%)]
MSM 142 (9.2) 21 (5.3) 121 (10.5) 0.020
IDU 1117 (72.5) 303 (77.1) 814 (70.9)
Haemophiliac 49 (3.2) 9 (2.3) 40 (3.5)
Heterosexual 186 (12.1) 49 (12.5) 137 (11.9)
Other 47 (3.1) 11 (2.8) 36 (3.1)
HCV genotype [n (%)]
1 896 (58.1) 227 (57.8) 669 (58.3) 0.0003
2 39 (2.5) 4 (1.0) 35 (3.1)
3 397 (25.7) 125 (31.8) 272 (23.7)
4 209 (13.6) 37 (9.4) 172 (15.0)
Baseline HBsAg status [n (%)]
Positive 95 (6.2) 31 (7.9) 64 (5.6) 0.012
Negative 1241 (80.5) 325 (82.7) 916 (79.8)
Unknown 205 (13.3) 37 (9.4) 168 (14.6)
Baseline CD4 count (cells/ml) [median (IQR)] 347 (200–518) 356 (204–510) 340 (197–526) 0.12
Baseline HCV RNA (log10 IU/ml) [median (IQR)] 5.82 (5.31–6.25) 5.78 (5.15–6.13) 5.85 (5.37–6.30) 0.0019
HIV RNA < 400 copies/ml [n (%)] 702 (47.6) 45 (11.8) 657 (60.1) < 0.0001
Baseline in this study was defined as the date of the first available HCV RNA measurement. cART was defined as at least three antiretrovirals from any class.
IQR, interquartile range; MSM, men who have sex with men; IDU, injecting drug user; HCV, hepatitis C virus; HBsAg, hepatitis B virus surface antigen.
*P-value from c2 test for comparison of proportions or Kruskal-Wallis test for comparison of population medians.
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negative and 6% were HBsAg positive, while for 13% the
HBsAg status was unknown. At baseline, those off and on
cART differed by age (median 33.9 vs. 38.4 years, respec-
tively; P < 0.0001), region of residence (28.2 vs. 37.4% in
southern Europe, 10.7 vs. 17.8% in eastern central Europe,
and 22.7 vs. 4.9% in eastern Europe, respectively; global
P < 0.0001), HIV transmission group [5.3 vs. 10.5% men
who have sex with men (MSM) and 77.1 vs. 70.9% IDUs,
respectively; global P = 0.02] and HCV genotype (31.8 vs.
23.7% HCV3 and 9.4 vs. 15.0% HCV4, respectively; global
P = 0.0003), while those on cART had a higher proportion
of individuals with HIV RNA < 400 copies/ml (11.8% for
those off cART vs. 60.1% for those on cART; P < 0.0001).
The median time from first HIVAb positive was 9.2 years
[interquartile range (IQR) 4.8-12.9 years], while the median
follow-up time (time from first to last HCV RNA measure-
ment) was 5.0 years (IQR 2.8–8.3 years); 575 individuals
had at least two HCV RNA measurements, the median
number of measurements per person was 2 (IQR 1–3, range
1-10), and the median time between measurements was
1.7 years (IQR 0.7–4.1 years).
The least squares mean estimates of HCV RNA levels and
percentage changes in HCV RNA over time from fitting the
mixed model detailed above are shown in Table 2. The 1541
individuals included in this model all contributed to esti-
mates of HCV RNA levels within each stratum; the 575
individuals with at least two HCV RNA measurements
contributed to the estimates for the change over time in
HCV RNA. Among patients not on cART, HCV RNA levels
increased by a mean 27.6% per year (95% CI 6.1–53.5%;
P = 0.0098). Among patients taking any form of cART,
HCV RNA levels remained stable, increasing by a mean
2.6% per year (95% CI -1.1 to 6.5%; P = 0.17) but not
significantly so. HCV RNA levels also stayed stable among
those taking PI-containing and NNRTI-containing regi-
mens [increases of 3.4% per year (95% CI -0.2 to 7.2%;
P = 0.068) and 2.0% per year (95% CI -5.2 to 9.7%;
P = 0.59), respectively], with no significant change over
time. Figure 1 shows the estimated HCV RNA trajectories
for each cART category.
Baseline HCV RNA levels were lower for HCV genotypes
2 to 4 compared with HCV genotype 1 (per cent difference
-25.5%; 95% CI -39.1 to -8.8%; P = 0.0044). There was
also some evidence to suggest that baseline HCV RNA
levels were lower among those in the haemophiliac HIV
transmission group compared with the IDU transmission
group (per cent difference -42.9%; 95% CI -68.5 to 3.6%;
P = 0.065), although this did not reach statistical signifi-
cance. There was borderline to weak statistical evidence to
suggest that HIV RNA levels above the level of detection
were associated with higher HCV RNA levels [per cent
differences 28.0% (95% CI -1.4 to 66.3%; P = 0.064),
32.4% (95% CI -0.8 to 76.7%; P = 0.057) and 32.5% (95%
CI -6.5 to 87.6%; P = 0.11) for HIV RNA 400–1000, 1000–
10 000 and > 10 000 copies/ml, respectively, compared with
< 400 copies/ml]. When HIV RNA was fitted as a continu-
ous variable on the log10 scale, it became a significant
predictor of HCV RNA, with HCV RNA increasing by 10.9%
per log10 change in HIV RNA (95% CI 2.3 to 20.2%;
P = 0.012). When age per 10 years and CD4 cell count on
the log2 scale were fitted as continuous variables, the
associations did not approach statistical significance
(P = 0.31 and P = 0.81, respectively).
No interactions between covariates in the mixed model
and time were statistically significant except for the cART
by time interaction (P = 0.023), indicating that the rate of
change in HCV RNA over time was only affected by cART
in this population.
In a multivariable logistic regression model adjusting for
age, HCV genotype, gender, ethnicity, region of Europe,
HIV exposure group, HBsAg status, cART initiation status,
HIV RNA and CD4 cell count, individuals with an increase
in HCV RNA of more than the 90th percentile (a 10%
increase per year) were more likely to have HCV genotype
1 than 2, 3 or 4 [adjusted odds ratio (aOR) 1.37; 95% CI
1.01–1.86; P = 0.042]. In a similar model adjusted for the
same factors as above, individuals with a decrease in HCV
RNA of more than the 10th percentile (a 7% decrease per
year) were less likely to reside in eastern central or eastern
Europe compared with southern Europe [aOR 0.43 (95% CI
0.22–0.84; P = 0.013) and aOR 0.40 (95% CI 0.17–0.94;
P = 0.035), respectively]. In a similar model adjusted for the
same factors, HCV genotype 1 was a significant predictor
of reaching a threshold of 800 000 IU/ml in HCV RNA [aOR
1.45 (95% CI 1.17–1.77; P = 0.0006) compared with geno-
types 2, 3 and 4], along with residing in western Europe
[aOR 1.71 (95% CI 1.24–2.34; P = 0.0010) compared with
southern Europe].
A number of sensitivity analyses were performed to
further examine the increase in HCV RNA levels over time.
Including only the 258 individuals with three or more HCV
RNA measurements, the increase in HCV RNA over time
among patients not on cART was 38.9% per year (95% CI
0.7 to 91.8%; P = 0.046), while for patients taking any
cART HCV RNA was again stable through time, increasing
by 1.2% per year (95% CI -4.7 to 7.4%; P = 0.70). Among
patients on a PI regimen HCV RNA was stable, with an
increase of 3.2% per year (95% CI -3.2 to 10.1%; P = 0.33),
while for those on an NNRTI regimen it was also stable,
with an increase of 0.2% per year (95% CI -33.2 to 56.3%;
P = 0.92).
A further sensitivity analysis including those with three
or more HCV RNA measurements, using only data collected
from sites and not from stored samples to exclude the
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possibility that changes in HCV RNA could be explained by
degradation over time of stored plasma samples, found
that, among patients not on cART, HCV RNA increased by
20.9% per year (95% CI -16.9 to 75.9%; P = 0.32), although
not significantly so as a consequence of the reduced power
of this analysis, which included data from 169 patients. In
those on any cART, HCV RNA levels again remained stable,
with an estimated decrease of 3.1% per year (95% CI -11.1
to 5.6%; P = 0.47).
Discussion
This study examined the natural history of plasma HCV
RNA in chronically HCV/HIV-coinfected individuals. The
Table 2 Least squares (LS) estimates of hepatitis C virus (HCV) RNA levels and changes through time
LS means at baseline*
(log10 IU/ml)
Difference within strata at baseline Change in HCV RNA over time
% (95% CI) P-value† % per year (95% CI) P-value‡
cART status
None 5.50 0 – – 27.6 (6.1, 53.5) 0.0098
All cART 5.61 26.8 (-3.0,65.8) 0.083 2.6 (-1.1,6.5) 0.17
PI regimen 5.59 9.4 (-13.4,38.4) 0.45 3.4 (-0.2,7.2) 0.068
NNRTI regimen 5.65 27.4 (-24.0,113.5) 0.35 2.0 (-5.2,9.7) 0.59
HCV genotype
1 5.62 0 – –
2, 3 or 4 5.49 -25.5 (-39.1,-8.8) 0.0044
Baseline age
< 30 years 5.48 0 – –
30–40 years 5.56 20.9 (-12.8,67.5) 0.25
40–50 years 5.58 27.3 (-12.3,84.8) 0.20
> 50 years 5.60 30.8 (-21.0,116.5) 0.30
Gender
Male 5.58 0 – –
Female 5.53 -11.0 (-28.9,11.4) 0.31
Race
White 5.53 0 – –
Nonwhite 5.58 10.6 (-24.9,62.3) 0.61
Region of Europe/country
Southern 5.56 0 – –
Western central 5.60 10.7 (-17.1,47.8) 0.49
Northern 5.59 8.4 (-21.4,49.7) 0.62
Eastern central 5.63 19.7 (-15.0,68.4) 0.31
Eastern 5.54 -2.6 (-39.5,56.9) 0.92
Argentina 5.41 -29.2 (-66.3,48.6) 0.36
HIV transmission group
Injecting drug user 5.65 0 – –
MSM 5.52 -25.3 (-48.1,7.4) 0.12
Haemophiliac 5.41 -42.9 (-68.5.3.6) 0.065
Heterosexual 5.57 -17.2 (-40.0,14.3) 0.25
Other 5.63 -3.5 (-45.1,69.5) 0.90
HIV RNA
< 400 copies/ml 5.47 0 – –
400–1000 copies/ml 5.58 28.0 (-1.4,66.3) 0.064
1000–10 000 copies/ml 5.59 32.4 (-0.8,76.7) 0.057
> 10 000 copies/ml 5.59 32.5 (-6.5,87.6) 0.11
CD4 count
> 500 cells/mL 5.54 0 – –
350–500 cells/mL 5.55 2.2 (-22.6,35.0) 0.88
200–350 cells/mL 5.54 -1.1 (-23.0,27.2) 0.93
< 200 cells/mL 5.59 11.7 (-11.7,41.4) 0.36
HBsAg status
Negative 5.61 0 – –
Positive 5.50 -21.9 (-47.9,16.9) 0.23
Unknown 5.55 -13.6 (-36.9,18.4) 0.36
cART, combination antiretroviral therapy; CI, confidence interval; MSM, men who have sex with men; NNRTI, nonnucleoside reverse transcriptase inhibitor;
PI, protease inhibitor.
*Least squares mean estimates of HCV RNA levels in each stratum accounting for confounding.
†P-value for comparisons of baseline HCV RNA levels within each stratum.
‡P-value for increase through time of HCV RNA compared with null hypothesis of no increase in HCV RNA through time.
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results show that, among patients not on cART, HCV RNA
levels increased over time by 27.6% per year, compared
with a nonsignificant 2.6% increase per year among
patients treated with cART. Further, patients taking a
PI-containing regimen had a nonsignificant 3.4% increase
per year, while those taking an NNRTI-containing regimen
had a nonsignificant 2.0% increase per year. This finding
adds to the body of work on the topic, such as a study from
the USA of coinfected IDUs [4] which found small increases
in HCV RNA for coinfected individuals in the region of 2%
per year and increases of 6% per year in monoinfected
individuals; unfortunately, whether patients were treated
with cART was not mentioned in this study but our results
would suggest that they were. A study in a cohort of
coinfected haemophiliacs [17] also showed 8-fold higher
increases in HCV RNA among HIV-positive patients com-
pared with HIV-negative patients. One study in a cohort of
haemophiliacs in the UK [14] found evidence of an increase
in HCV RNA in the first 4 years after HIV seroconversion,
after which HCV RNA appeared to stabilize. One benefit of
our study is the long duration of follow-up in the cohort;
the median time from first HIVAb positive to first HCV RNA
measurement was 9.2 (IQR 4.8–12.9) years, meaning we
have evidence to suggest that the increase in HCV RNA
continues beyond this 4-year period in the absence of
treatment for HIV infection, assuming individuals were
infected with HCV before or at the same time they became
HIV positive. For IDUs, which make up the majority of the
study population, this is a reasonable assumption to make
because of the shared transmission routes of HIV and HCV,
although it is less likely to be the case for MSM and
heterosexuals as sexual transmission of HCV is less effi-
cient than that of HIV [20].
While an increase in HCV RNA of 27.6% per year
appears quite striking, we have demonstrated that treat-
ment with cART can stabilize HCV RNA levels in coinfected
patients. It is unclear how much influence increasing HCV
RNA levels will have on clinician choice when deciding
whether to treat for HCV while the association between
HCV viral load, disease severity and liver disease remains
unclear [16,21]. More weight will often be given to other
factors, such as level of fibrosis, HCV genotype, IL-28B
gene variant and a patient’s readiness for treatment [1,22].
However, with recent studies suggesting a link between
high HCV viral loads (> 500 000 IU/ml) and progression to
chronic kidney disease [23,24], increasing HCV RNA could
become more clinically important in the future.
HIV viral load when fitted on a log10 continuous scale
was found to have a significant relationship with HCV
RNA, which further supports our finding that treatment
with cART can help to control HCV RNA. These findings,
building on evidence from a similar study [4], have poten-
tial implications for the treatment of persons with HCV/
HIV coinfection. As lower HIV viral loads predict lower
HCV RNA, which is known to be one of the most important
predictors of HCV treatment outcome [25], it may be pos-
sible to improve the chances of SVR to HCV treatment by
controlling HIV viral load and indirectly stabilizing HCV
RNA levels in the absence of HCV therapy. However, a
short-term transient increase in HCV RNA has been
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Fig. 1 Estimated hepatitis C virus (HCV) RNA trajectories match the baseline HCV RNA levels and change through time estimated from mixed
models. cART, combination antiretroviral therapy; NNRTI, nonnucleoside reverse transcriptase inhibitor; PI, protease inhibitor.
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reported in coinfected persons initiating cART [26,27],
while another study reported that those with low CD4
counts (< 350 cells/mL) at cART initiation experienced a
continuous increase in HCV RNA levels for the 48-week
duration of the study [28]. Further, a recent study with a
long follow-up period found that there was a small
increase in HCV RNA 6 months after cART initiation but a
significant decrease in HCV RNA at 70 months after cART
initiation [29].
Other studies which have examined the course of HCV
RNA levels at 3 and 12 months after the initiation of cART
have produced conflicting results [26]. Different studies
have found increases and decreases in HCV RNA levels at
these time-points following cART initiation, although often
the changes were not significant and the results were based
on a small number of individuals [30]. It is difficult for us to
examine the potential nonlinearity of the course of HCV
RNA, attributable to cART initiation, at these time points as
74.5% of patients were on cART at baseline, with a median
time on cART of 2.7 years (IQR 1.0–5.3 years). Interaction
terms allowing the rate of change in HCV RNA to differ at 3
and 12 months after cART initiation were excluded from the
model as they were nonsignificant (results not shown),
meaning we have no evidence to suggest that the linearity
of HCV RNA changes over time was affected by cART
initiation.
HCV genotype 1 was a significant predictor of higher
HCV RNA levels compared with genotypes 2, 3 and 4.
Similarly, some previous studies have shown an association
between higher HCV RNA levels and HCV genotype 1 [2,4],
although this has not been seen in others [16,21]; however,
these studies have tended to include relatively few indi-
viduals, predominantly with HCV genotype 1. Increases in
HCV RNA of more than 10% per year (the 90th percentile)
were also found to be associated with HCV genotype 1, as
was reaching a threshold of 800 000 IU/ml, which has been
reported to be a predictor of a poor response to treatment
for HCV [12]. These findings highlight HCV genotype 1 as
the most difficult for which to control HCV RNA levels.
EuroSIDA has previously published a comparison of base-
line HCV RNA levels by genotype [19], but the present
study adds important information and considers longitu-
dinal changes in HCV RNA for genotypes 1 to 4 in a
relatively large number of individuals.
We found no evidence that HBsAg status influences HCV
RNA levels, although baseline HCV RNA levels were lower
among HBsAg-positive patients but not significantly so.
Many studies have reported that the presence of HBV may
favour the clearance of HCV RNA in patients with multiple
chronic viral hepatitis infections [19,31,32], including
another EuroSIDA study [19]. The fact that HBsAg was not
found to be associated with HCV RNA levels in this study
could be explained by the low number of HBsAg-positive
persons included, 6.2% at baseline, and the length of time
since HCV seroconversion. It is possible that, among the
previously multiply coinfected individuals, suppression of
HCV had already occurred as a result of the presence of
HBV and that these individuals were HCV RNA negative
when testing began.
We found no evidence to suggest that the rate of change
in HCV RNA differed by any factors included in the model
other than cART. However, we had limited power to detect
these differences in the rate of change because of the
relatively low number of HCV RNA measurements per
person. Further studies are required to fully understand the
rate of change in HCV RNA levels and how it may differ
according to genotype or other factors, something that
could be revisited in time when more data are collected.
Our study has several limitations; most significantly,
there were relatively few individuals in our cohort with
multiple HCV RNA measurements. Of the 1541 individuals
included in the analysis, 258 had three or more HCV RNA
determinations. In a sensitivity analysis including only
these individuals, HCV RNA increased by 38.9% per year in
patients not on cART and was stable, with an increase of
1.2% per year, among those taking any cART. A further
sensitivity analysis including data from individuals with
three or more HCV RNA measurements using data collected
from sites only, excluding data from stored samples to
discount the possible effect of degradation of HCV RNA in
stored samples, produced similar results, a 20.7% increase
in HCV RNA among those not on cART and a 3.1%
decrease among those taking cART, although with reduced
statistical significance because of the relatively small
number of patients included.
In conclusion, this study demonstrated that, while HCV
RNA levels increased during long-term follow-up in coin-
fected patients not taking cART, among those who had
initiated cART HCV RNA levels were stable over time,
suggesting that earlier treatment with cART could help to
control HCV RNA levels.
Acknowledgements
Conflicts of interest: OK has received honorarium, consul-
tancy and/or lecture fees from Abbot, Gilead, Janssen,
Merck and Viiv. Jürgen Rockstroh has received consultancy
or lecture fees from Bionor, BMS, BI, GSK, ViiV, Abbott,
Gilead, Pfizer, Merck, Tibotec and Janssen. AM has received
honorarium, consultancy or guest speaker fees from Pfizer,
Merck, Gilead, BI and BMS. All other authors have no
conflicts of interest to report.
Funding: Primary support for EuroSIDA is provided
by the European Commission BIOMED 1 (CT94-1637),
376 D Grint et al.
© 2013 British HIV Association HIV Medicine (2013), 14, 370–378
BIOMED 2 (CT97-2713), 5th Framework (QLK2-2000-
00773), 6th Framework (LSHP-CT-2006-018632) and 7th
Framework (FP7/2007-2013, EuroCoord no. 260694) pro-
grammes. Current support also includes unrestricted grants
from Gilead, Pfizer, BMS, and Merck and Co. The partici-
pation of centres in Switzerland was supported by The
Swiss National Science Foundation (grant 108787).
References
1 Soriano V, Puoti M, Sulkowski M et al. Care of patients
coinfected with HIV and hepatitis C virus: 2007 updated
recommendations from the HCV-HIV International Panel.
Aids 2007; 21: 73–89.
2 Soriano V, Vispo E, Labarga P, Medrano J, Barreiro P. Viral
hepatitis and HIV co-infection. Antiviral Res 2010; 85: 3–15.
3 Eyster ME, Diamondstone LS, Lien JM, Ehmann WC, Quan S,
Goedert JJ. Natural-history of hepatitis-C virus-infection in
multitransfused hemophiliacs – effect of coinfection with
human-immunodeficiency-virus. J Acquir Immune Defic
Syndr Hum Retrovirol 1993; 6: 2–10.
4 Fishbein DA, Lo YT, Netski D, Thomas DL, Klein RS.
Predictors of hepatitis C virus RNA levels in a prospective
cohort study of drug users. Jaids J Acquir Immune Defic
Syndr 2006; 41: 71–76.
5 Lesens O, Deschenes M, Steben M, Belanger G, Tsoukas CM.
Hepatitis C virus is related to progressive liver disease in
human immunodeficiency virus-positive hemophiliacs and
should be treated as an opportunistic infection. J Infect Dis
1999; 179: 254–258.
6 Rockstroh JK, Mocroft A, Soriano V et al. Influence of
hepatitis C virus infection on HIV-1 disease progression and
response to highly active antiretroviral therapy. J Infect Dis
2005; 192: 92–1002.
7 Bonacini M, Louie S, Bzowej N, Wohl AR. Survival in
patients with HIV infection and viral hepatitis B or C: a
cohort study. Aids 2004; 18: 39–45.
8 Mocroft A, Soriano V, Rockstroh J et al. Is there evidence
for an increase in the death rate from liver-related disease in
patients with HIV? Aids 2005; 19: 117–125.
9 Weber R. Liver-related deaths in persons infected with the
human immunodeficiency virus – The D : A : D study. Arch
Intern Med 2006; 166: 632–641.
10 Weis N, Lindhardt BO, Kronborg G et al. Impact of hepatitis
C virus coinfection on response to highly active
antiretroviral therapy and outcome in HIV-infected
individuals: a Nationwide Cohort Study. Clin Infect Dis
2006; 42: 481–487.
11 Soriano V, Garcia-Samaniego J, Rodriguez-Rosado R,
Gonzalez J, Pedreira J. Hepatitis C and HIV infection:
biological, clinical, and therapeutic implications. J Hepatol
1999; 31: 119–123.
12 Torriani FJ, Rodriguez-Torres M, Rockstroh JK et al.
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C
virus infection in HIV-infected patients. N Engl J Med 2004;
351: 38–50.
13 McCarthy JJ, Li JH, Thompson A et al. Replicated association
between an IL28B gene variant and a sustained response to
pegylated interferon and ribavirin. Gastroenterology 2010;
138: 307–314.
14 Herrero-Martinez E, Sabin CA, Evans JG, Griffioen A, Lee
CA, Emery VC. The prognostic value of a single hepatitis C
virus RNA load measurement taken early after human
immunodeficiency virus seroconversion. J Infect Dis 2002;
186: 70–76.
15 Thomas DL, Astemborski J, Vlahov D et al. Determinants of
the quantity of hepatitis C virus RNA. J Infect Dis 2000;
181: 44–51.
16 Yeo AET, Ghany M, Conry-Cantilena C et al. Stability of
HCV-RNA level and its lack of correlation with disease
severity in asymptomatic chronic hepatitis C virus carriers.
J Viral Hepat 2001; 8: 56–63.
17 Eyster ME, Fried MW, Dibisceglie AM, Goedert JJ. Increasing
hepatitis-C virus-rna levels in hemophiliacs – relationship to
human-immunodeficiency-virus infection and liver-disease.
Blood 1994; 84: 020–023.
18 Mocroft A, Ledergerber B, Katlama C et al. Decline in the
AIDS and death rates in the EuroSIDA study: an
observational study. Lancet 2003; 362: 2–9.
19 Soriano V, Mocroft A, Rockstroh J et al. Spontaneous viral
clearance, viral load, and genotype distribution of hepatitis
C virus (HCV) in HIV-infected patients with anti-HCV
antibodies in Europe. J Infect Dis 2008; 198: 337–344.
20 Tohme RA, Holmberg SD. Is sexual contact a major mode
of hepatitis C Virus transmission? Hepatology 2010; 52:
497–505.
21 Hollingsworth RC, Sillekens P, vanDeursen P, Neal KR,
Irving WL. Serum HCV RNA levels assessed by quantitative
NASBA(R): stability of viral load over time, and lack of
correlation with liver disease. J Hepatol 1996; 25: 01–06.
22 Chen Y. Meta-analysis: IL28B polymorphisms predict
sustained viral response in HCV patients treated with
pegylated interferon-a and ribavirin. Aliment Pharmacol
Ther 2012; 36: 1–103.
23 Peters L, Grint D, Lundgren JD et al. Chronic Hepatitis C
(HCV) Infection and Chronic Kidney Disease (CKD) in
HIV-infrected Patients in the EuroSIDA Study. 13th
European Aids Conference (EACS). Belgrade, Serbia, October
2011 [Abstract PS7/3].
24 Mocroft A, Neuhaus J, Peters L et al. for the INSIGHT
SMART and ESPRIT Study Groups. Hepatitis B and C
co-infection are independent predictors of progressive
kidney disease in HIV-positive, antiretroviral-treated adults.
PLoS ONE 2012; 7: e40245.
Longitudinal changes in HCV RNA 377
© 2013 British HIV Association HIV Medicine (2013), 14, 370–378
25 Thompson AJ, Muir AJ, Sulkowski MS et al. Interleukin-28B
polymorphism improves viral kinetics and is the strongest
pretreatment predictor of sustained virologic response in
genotype 1 hepatitis C virus. Gastroenterology 2010; 139:
20–U178.
26 Bower WA, Culver DH, Castor D et al. Changes in hepatitis C
virus (HCV) viral load and interferon-alpha levels in
HIV/HCV-coinfected patients treated with highly active
antiretroviral therapy. Jaids J Acquir Immune Defic Syndr
2006; 42: 93–97.
27 Rutschmann OT, Negro F, Hirschel B, Hadengue A,
Anwar D, Perrin LH. Impact of treatment with human
immunodeficiency virus (HIV) protease inhibitors on
hepatitis C viremia in patients coinfected with HIV.
J Infect Dis 1998; 177: 83–85.
28 Chung RT, Evans SR, Yang YJ et al. Immune recovery is
associated with persistent rise in hepatitis C virus RNA,
infrequent liver test flares, and is not impaired by hepatitis
C virus in co-infected subjects. Aids 2002; 16: 915–923.
29 Rohrbach J, Robinson N, Harcourt G et al. Cellular immune
responses to HCV core increase and HCV RNA levels
decrease during successful antiretroviral therapy. Gut 2010;
59: 252–258.
30 Cooper C. Review of the effect of highly active antiretroviral
therapy on hepatitis C virus (HCV) RNA levels in human
immunodeficiency virus and HCV coinfection. Clin Infect Dis
2002; 35: 73–79.
31 Konopnicki D, Mocroft A, de Wit S et al. Hepatitis B and
HIV: prevalence, AIDS progression, response to highly active
antiretroviral therapy and increased mortality in the
EuroSIDA cohort. Aids 2005; 19: 93–601.
32 Martin-Carbonero L, Barreiro P, Jimenez-Galan G,
Garcia-Berriguete R, Nunez M. Clearance of hepatitis C virus
in HIV-infected patients with multiple chronic viral hepatitis.
J Viral Hepat 2007; 14: 92–95.
Supporting information
Additional Supporting Information may be found in the
online version of this article at the publisher’s web-site.
Appendix S1. The EuroSIDA study group.
378 D Grint et al.
© 2013 British HIV Association HIV Medicine (2013), 14, 370–378
